New trends in the treatment of Hodgkin's disease

Over the past several years, much progress has been made in the treatment of Hodgkin's disease (HD), with 5-year overall survival rates ranging from 60 to 95%, according to initial prognostic factors. This optimism has been tempered by the development of late complications in long-term HD survivors, in particular second neoplasms and cardiac toxicity. At present, new treatments aimed at maintaining high event-free survival and reducing long-term adverse effects are being studied. To be successful, the treatment must be tailored according to prognostic factors.